Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors

Diseases of the Colon and Rectum

Volumn 39, Issue 11, 1996, Pages 1269-1274

  Shibata, Yutaka ^a   Kotanagi, Hitoshi ^a   Andoh, Hideaki ^a   Koyama, Kenji ^a   Itoh, Hideaki ^a   Kudo, Shin Ei ^b  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AKITA RED CROSS HOSPITAL   (Japan)

Author keywords

Circulating anti p53 antibody; Colorectal carcinoma; Tumor marker

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; TUMOR SUPPRESSOR GENE;

EID: 0029912778     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02055121     Document Type: Article

References (29)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
3. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-703.
4. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-21.
5. Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52:1974-80.
6. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-22.
7. Gronostajski RM, Goldberg AL, Pardee AB. Energy requirement for degradation of tumor-associated protein p53. Mol Cell Biol l984;4:442-8.
8. Stzbecher H, Chumakov P, Welch WJ, Jenkins JR. Mutant p53 proteins bind hsp72/73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene 1987;1:201-11.
9. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8: 531-9.
10. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-8.
11. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992;89:3439-42.
12. Schlichtholz B, Legros Y, Gillet D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-4.
13. Volkmann M, Müler M, Hofmann WJ, et al.The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology 1993;18:59-65.
14. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52;4168-74.
15. Hassapoglidou S, Diamandis EP. Antibodies to the p53 tumor suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. Clin Biochem 1992;25:445-9.
16. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987;39:185-9.
17. Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993;53:3468-71.
18. Hinds PW, Finlay CA, Frey AB, Levine AJ. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol 1987;7:2863-9.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
20. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamid gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
21. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
22. Gatlin CL, Schaberg ES, Jordan WH, Kuyatt BL, Smith WC. Point counting on the Macintosh: a semiautomated image analysis technique. Anal Quant Cytol Histol 1993;15:343-50.
23. Turnbull RB, Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technic on survival rates. Ann Surg 1967;166:420-7.
24. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
25. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991;65:765-74.
26. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
27. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990;5:945-52.
28. Nakamura T, Yana I, Kobayashi T, et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992;83: 1293-8.
29. Ito T, Seyama T, Mizuno T, et al. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 1993;84:526-31.